The agency gives the nod to Ryzolt (tramadol HCl extended-release tablets), a once-daily formulation of the analgesic tramadol. Ryzolt is indicated for the management of moderate-to-moderately severe chronic pain in adults who require long-term, around-the-clock pain treatment.